Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study

ConditionsADHD Primary Nocturnal Enuresis

Trial statusNot yet recruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age6-12

SponsorTanta University

About this trial

1. Primary Aim: To evaluate the efficacy of atomoxetine in reducing the frequency of primary nocturnal enuresis episodes in children with ADHD. 2. Secondary Aim: To determine if improvements in attention symptoms correlate with reductions in nocturnal enuresis episodes.

Eligibility criteria

Qualifiers

Children aged 6-12 years diagnosed with ADHD per Conners-48 scale. Children experiencing primary nocturnal enuresis.

Disqualifiers

Secondary causes of enuresis (e.g., urinary tract infections, diabetes). Use of other enuresis treatments. Known contraindications to atomoxetine.

Trial design

Treatments tested in this trial

Atomoxetine
Placebo

Treatment groups

100 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Tanta University

Lead sponsor

Source ClinicalTrials.gov